Oxford Biomedica plc announced that Sanofi has given notice that they intend to terminate the Collaboration and License Agreement for process development and manufacturing of lentiviral vectors to treat haemophilia. Oxford Biomedica had originally signed the Collaboration and License Agreement with Bioverativ in February 2018. The Group expects that the impact on revenue will be negligible over the coming 24 month period.